Radiopharm Theranostics Limited
Australian Securities ExchangeTotal Valuation
Radiopharm Theranostics Limited carries a market capitalization of 47.30M, placing it among publicly traded companies globally.
| Market Cap | 47.30M |
| Enterprise Value | N/A |
Share Statistics
Radiopharm Theranostics Limited currently has 2.20B shares outstanding.
| Shares Outstanding | 2.20B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Radiopharm Theranostics Limited maintains a current ratio of 3.37, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.37 |
| Quick Ratio | 3.25 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Stock Price Statistics
Radiopharm Theranostics Limited's stock has declined approximately -9.09091% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | -9.09091% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Average Volume (20 Days) | N/A |
Balance Sheet
Total book value stands at 40.50M, with working capital of 31.21M providing operational flexibility.
| Cash & Cash Equivalents | 36.44M |
| Total Debt | N/A |
| Net Debt | -36.44M |
| Equity (Book Value) | 40.50M |
| Book Value Per Share | N/A |
| Working Capital | 31.21M |
Stock Splits
Radiopharm Theranostics Limited's most recent stock split took place on November 2, 2023 with a 500:529 split ratio.
| Last Split Date | 11/2/2023 |
| Split Ratio | 500:529 |
Scores
Radiopharm Theranostics Limited posts an Altman Z-Score of -3.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.18 |